ESTRO 2022 | Subgroup analysis from SAFE trial: pharmacological cardioprotective strategies for breast cancer

Icro Meattini, MD, University of Florence, Florence, Italy, gives an update on the interim analysis results from the Phase III SAFE trial (NCT02236806) investigating pharmacological preventative strategies against cardiotoxicity in patients with breast cancer who were treated with anthracyclines and/or trastuzumab. The subgroup analysis presented at ESTRO 2022 looked at patients in the trial who received radiotherapy, and whether this had an impact on the protective effect of the pharmacological interventions. This interview took place at the European Society for Radiotherapy and Oncology (ESTRO) 2022 annual congress in Copenhagen, Denmark, and online.